Evidence map›Paper›PMID 34828568›Full record

ArticleHealthcare (Basel, Switzerland)2021

The Impact of the COVID-19 Pandemic on Cancer Patient's Management-Lithuanian Cancer Center Experience.

Daiva Dabkeviciene, Ieva Vincerzevskiene, Vincas Urbonas, Jonas Venius, Audrius Dulskas, Birute Brasiuniene, Ernestas Janulionis, Arvydas Burneckis, Asta Zileviciene, Sigitas Tiskevicius and 20 more

Open access · goldAbstract read
In one paragraph

Article in Healthcare (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
1.4field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Hidden Costs of the COVID-19 Pandemic Response.International journal of environmental research and public health · 2023
    Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

30 authors at 1 institution in 1 country.

Daiva DabkevicieneBiobank, National Cancer Institute, 08406 Vilnius, Lithuania.
Ieva VincerzevskieneCancer Registry, National Cancer Institute, 08406 Vilnius, Lithuania.
Vincas UrbonasLaboratory of Clinical Oncology, National Cancer Institute, 08406 Vilnius, Lithuania.ORCID 0000-0002-8070-6163
Jonas VeniusDepartment of Medical Physics, National Cancer Institute, 08406 Vilnius, Lithuania.
Audrius DulskasLaboratory of Clinical Oncology, National Cancer Institute, 08406 Vilnius, Lithuania.ORCID 0000-0003-3692-8962
Birute BrasiunieneBiobank, National Cancer Institute, 08406 Vilnius, Lithuania.
Ernestas JanulionisDepartment of Brachyterapy, National Cancer Institute, 08406 Vilnius, Lithuania.
Arvydas BurneckisDepartment of Radiation Oncology, National Cancer Institute, 08406 Vilnius, Lithuania.
Asta ZilevicieneDepartment of External Beam Radiotherapy, National Cancer Institute, 08406 Vilnius, Lithuania.
Sigitas TiskeviciusDepartment of Nuclear Medicine, National Cancer Institute, 08406 Vilnius, Lithuania.
Rasa Vanseviciute-PetkevicieneOutpatients Department, National Cancer Institute, 08406 Vilnius, Lithuania.
Jurgita UsinskieneDepartment of Radiology, National Cancer Institute, 08406 Vilnius, Lithuania.
Ruta BriedieneDepartment of Radiology, National Cancer Institute, 08406 Vilnius, Lithuania.
Giedre BulotieneOutpatients Department, National Cancer Institute, 08406 Vilnius, Lithuania.ORCID 0000-0002-4536-6669
Eugenijus StratilatovasLaboratory of Clinical Oncology, National Cancer Institute, 08406 Vilnius, Lithuania.
Valerijus OstapenkoLaboratory of Clinical Oncology, National Cancer Institute, 08406 Vilnius, Lithuania.
Jolita GibavicieneLaboratory of Clinical Oncology, National Cancer Institute, 08406 Vilnius, Lithuania.
Ignas KarnasDepartment of ENT, Head and Neck Surgery, National Cancer Institute, 08406 Vilnius, Lithuania.
Saule KekstaiteDepartment of ENT, Head and Neck Surgery, National Cancer Institute, 08406 Vilnius, Lithuania.
Jurgita NavickieneDepartment of ENT, Head and Neck Surgery, National Cancer Institute, 08406 Vilnius, Lithuania.
Albertas UlysLaboratory of Clinical Oncology, National Cancer Institute, 08406 Vilnius, Lithuania.
Algirdas ZalimasLaboratory of Clinical Oncology, National Cancer Institute, 08406 Vilnius, Lithuania.
Algimantas SruogisDepartment of Oncourology, National Cancer Institute, 08406 Vilnius, Lithuania.ORCID 0000-0001-7514-7574
Zygimantas KardelisDepartment of Oncourology, National Cancer Institute, 08406 Vilnius, Lithuania.
Sigitas ZarembaDepartment of Thoracic Surgery, National Cancer Institute, 08406 Vilnius, Lithuania.
Renatas AskinisDepartment of Thoracic Surgery, National Cancer Institute, 08406 Vilnius, Lithuania.
Saulius CicenasLaboratory of Clinical Oncology, National Cancer Institute, 08406 Vilnius, Lithuania.
Renatas TikuisisDepartment of Anesthesiology and Intensive Care, National Cancer Institute, 08406 Vilnius, Lithuania.
Ruta CiurlieneDepartment of Oncogynecology, National Cancer Institute, 08406 Vilnius, Lithuania.
Sonata JarmalaiteLaboratory of Clinical Oncology, National Cancer Institute, 08406 Vilnius, Lithuania.
National Cancer Institute · LT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The pandemic spread of the COVID-19 virus significantly affected daily life, but the highest pressure was piled on the health care system. Our aim was to evaluate an impact of COVID-19 pandemic management measures on cancer services at the National Cancer Institute (NCI) of Lithuania. We assessed the time period from 1 February 2020 to 31 December 2020 and compared it to the same period of 2019. Data for our analysis were extracted from the NCI Hospital Information System (HIS) and the National Health Insurance Fund (NHIF). Contingency table analysis and ANOVA were performed. The COVID-19 pandemic negatively affected the cancer services provided by NCI. Reductions in diagnostic radiology (-16%) and endoscopy (-29%) procedures were accompanied by a decreased number of patients with ongoing medical (-30%), radiation (-6%) or surgical (-10%) treatment. The changes in the number of newly diagnosed cancer patients were dependent on tumor type and disease stage, showing a rise in advanced disease at diagnosis already during the early period of the first lockdown. The extent of out-patient consultations (-14%) and disease follow-up visits (-16%) was also affected by the pandemic, and only referrals to psychological/psychiatric counselling were increased. Additionally, the COVID-19 pandemic had an impact on the structure of cancer services by fostering the application of modified systemic anticancer therapy or hypofractionated radiotherapy. The most dramatic drop occurred in the number of patients participating in cancer prevention programs; the loss was 25% for colon cancer and 62% for breast cancer screening. Marked restriction in access to preventive cancer screening and overall reduction of the whole spectrum of cancer services may negatively affect cancer survival measures in the nearest future.

Indexed as

cancer managementCOVID-19 pandemicnational lockdown

Identifiers

PMID34828568
PMCPMC8623620
OpenAlexW3212149337

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.